Match!
Charles Swanton
Francis Crick Institute
CancerPathologyBreast cancerMedicineBiology
342Publications
66H-index
28.9kCitations
What is this?
Publications 355
Newest
#1Saioa López (UCL: University College London)H-Index: 8
#3Emilia L. Lim (UCL: University College London)H-Index: 1
Last. Andrew Rowan (UCL: University College London)H-Index: 49
view all 16 authors...
Whole-genome doubling (WGD) is a prevalent event in cancer, involving a doubling of the entire chromosome complement. However, despite its prevalence and prognostic relevance, the evolutionary selection pressures for WGD in cancer have not been investigated. Here, we combine evolutionary simulations with an analysis of cancer sequencing data to explore WGD during cancer evolution. Simulations suggest that WGD can be selected to mitigate the irreversible, ratchet-like, accumulation of deleterious...
Source
Source
Last. Charles Swanton (Francis Crick Institute)H-Index: 66
view all 8 authors...
By integrating discovery science with clinical practice and therapeutic intervention, clinician-scientists fulfil a unique role in cancer research. However, their numbers are in decline, which is creating the need for flexible training and research opportunities to ensure their future.
Source
#1Julianna Blagih (Francis Crick Institute)H-Index: 1
#2F Zani (Francis Crick Institute)
Last. Karen H. Vousden (Francis Crick Institute)H-Index: 89
view all 16 authors...
Summary Loss of p53 function contributes to the development of many cancers. While cell-autonomous consequences of p53 mutation have been studied extensively, the role of p53 in regulating the anti-tumor immune response is still poorly understood. Here, we show that loss of p53 in cancer cells modulates the tumor-immune landscape to circumvent immune destruction. Deletion of p53 promotes the recruitment and instruction of suppressive myeloid CD11b+ cells, in part through increased expression of ...
3 CitationsSource
#1Christine A. Iacobuzio-Donahue (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
#2Kevin Litchfield (UCL: University College London)
Last. Charles Swanton (UCL: University College London)H-Index: 66
view all 3 authors...
Intratumoral genetic heterogeneity of driver somatic mutations is present in a variety of tumor types, yet the extent of heterogeneity is variable. We propose that this variation is a reflection of the inherent biology of a given tumor type, representing the pace of metastatic dissemination and hence clinical disease course.
Source
#1Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
#2Daniel W. Bowles (University of Colorado Denver)H-Index: 19
Last. Charles Swanton (Francis Crick Institute)H-Index: 66
view all 14 authors...
Abstract Background Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics. Patients and Methods MyPathway is an ongoing, multiple basket, open-label, non-rando...
Source
#1Colin Watts (University of Birmingham)H-Index: 57
#2John R. Apps (University of Birmingham)
view all 23 authors...
Source
#1Adam Pennycuick (UCL: University College London)H-Index: 1
#2Vitor H. Teixeira (UCL: University College London)H-Index: 18
Last. Sam M. Janes (UCL: University College London)H-Index: 42
view all 29 authors...
Before squamous cell lung cancer develops, pre-cancerous lesions can be found in the airways. From longitudinal monitoring, we know that only half of such lesions become cancer, whereas a third spontaneously regress. While recent studies have described the presence of an active immune response in high-grade lesions, the mechanisms underpinning clinical regression of pre-cancerous lesions remain unknown. Here, we show that host immune surveillance is strongly implicated in lesion regression. Usin...
Source
#1Kevin Litchfield (Francis Crick Institute)H-Index: 14
#1Kevin Litchfield (Francis Crick Institute)H-Index: 5
Last. Charles Swanton (UCL: University College London)H-Index: 66
view all 19 authors...
Frameshift insertion/deletions (fs-indels) are an infrequent but potentially highly immunogenic mutation subtype. Although fs-indel transcripts are susceptible to degradation through the non-sense mediated decay (NMD) pathway, we hypothesise that some fs-indels escape degradation and lead to an increased abundance of tumor specific neoantigens, that are highly distinct from self. We analysed matched DNA and RNA sequencing data from TCGA, and five separate melanoma cohorts treated with immunother...
Source
#1Dhruva BiswasH-Index: 1
Last. Charles Swanton (Francis Crick Institute)H-Index: 66
view all 4 authors...
Abstract Background Molecular biomarkers aim to stratify cancer patients into disease subtypes predictive of outcome, improving diagnostic precision beyond clinical descriptors such as tumour stage. Transcriptomic intra-tumour heterogeneity (RNA-ITH) has been shown to confound existing expression-based biomarkers across multiple cancer types. Methods Here, we analyse multi-region whole-exome and RNA sequencing data for 156 tumour regions from 48 TRACERx patients to explore and control for RNA-IT...
Source
12345678910